Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Ryan Dillon"'
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 3 (2023)
Aim: This study evaluates the cost–effectiveness of imipenem/cilastatin/relebactam (IMI/REL) for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in an ‘early adjustment prescribing scenar
Externí odkaz:
https://doaj.org/article/79523ffb2a9a416a9a241f2e6a83809e
Publikováno v:
PLoS ONE, Vol 18, Iss 1, p e0279844 (2023)
We aimed to determine if available evidence from a previously conducted systematic literature review was sufficient to conduct a robust network meta-analysis (NMA) using the International Society for Pharmacoeconomics and Outcomes Research Good Pract
Externí odkaz:
https://doaj.org/article/96a142f2528d4c8c9e208516f02151b6
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 10, Iss 1, Pp 1-20 (2021)
Abstract Background Antibacterial-resistant gram-negative infections are a serious risk to global public health. Resistant Enterobacterales and Pseudomonas aeruginosa are highly prevalent, particularly in healthcare settings, and there are limited ef
Externí odkaz:
https://doaj.org/article/63d1619b84844f298c709e0c04a32756
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 4, Pp 953-966 (2020)
Abstract Introduction Hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) are associated with significant healthcare resource utilization (HCRU). This a priori, exploratory, secondary analysis from the ASPECT-NP clinical t
Externí odkaz:
https://doaj.org/article/b0c09aabe77e4ce19a08c673281d0f12
Autor:
Jonathan A.T. Sandoe, Kordo Saeed, Achyut Guleri, Kieran S. Hand, Ryan Dillon, Mike Allen, Amazigom Mayes, Fiona Glen, Armando Gonzalez-Ruiz
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 6 (2019)
Purpose: The objective of this prospective, observational study was to describe the treatment, severity assessment and healthcare resources required for management of patients with acute bacterial skin and skin structure infections who were unsuitabl
Externí odkaz:
https://doaj.org/article/3681723443a24ef1b6c1c0dd047de1cf
Autor:
Jean-Noel Trochu, Ryan Dillon, Finn Gustafsson, Stephen A. Mitchell, Veselin Mitrovic, Ottavio Alfieri
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 5, Iss C, Pp 26-41 (2014)
Background: The management of mitral regurgitation (MR) is challenging — patients may be asymptomatic, oligosymptomatic, older with comorbidities, or clinically symptomatic and not appropriate for surgery. The current review assesses morbidity, mor
Externí odkaz:
https://doaj.org/article/91e86cfdf0fc40e7a180b82bd07487f6
Autor:
Denise Marie A. Francisco, Liangliang Zhang, Ying Jiang, Adilene Olvera, Javier Adachi, Eduardo Yepez Guevara, Samuel L. Aitken, Kevin W. Garey, Christine B. Peterson, Kim-Anh Do, Ryan Dillon, Engels N. Obi, Robert Jenq, Pablo C. Okhuysen
Publikováno v:
Infectious Diseases and Therapy. 12:209-225
Infections caused by carbapenem-nonsusceptible gram-negative (C-NS) pathogens are associated with increased mortality and high treatment costs. Identification of potentially modifiable factors that may improve patient outcomes is important for better
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7ea9a0c2b20e04f5439ca37ca624c68
Autor:
Truc T Tran, Nicolo L Cabrera, Anne J Gonzales-Luna, Travis J Carlson, Faris Alnezary, William R Miller, Aki Sakurai, An Q Dinh, Kirsten Rydell, Rafael Rios, Lorena Diaz, Blake M Hanson, Jose M Munita, Claudia Pedroza, Samuel A Shelburne, Samuel L Aitken, Kevin W Garey, Ryan Dillon, Laura Puzniak, Cesar A Arias
Publikováno v:
JAC-antimicrobial resistance. 5(1)
Background Ceftolozane/tazobactam is a β-lactam/β-lactamase inhibitor combination with activity against a variety of Gram-negative bacteria, including MDR Pseudomonas aeruginosa. This agent is approved for hospital-acquired and ventilator-associate
Publikováno v:
PloS one. 18(1)
We aimed to determine if available evidence from a previously conducted systematic literature review was sufficient to conduct a robust network meta-analysis (NMA) using the International Society for Pharmacoeconomics and Outcomes Research Good Pract